Influence of the esterase inhibitor sodium fluoride on whole blood or serum concentrations of common psychotropic drugs and substitution therapeutics

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021579

Enrollment

100

Registered

2020-04-27

Start date

2020-06-08

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

They are no certain diseases to be investigated. The selection criteria are the intake of certain drugs that are used due to different indications.

Interventions

Group 1: Blood samples of patients taking at least one of the following drugs are analyzed: clonazepam, oxazepam, diazepam, citalopram or escitalopram, venlafaxine, fluoxetine, paroxetine, sertraline,

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients taking at least one of the psychotropic drugs or substitution therapeutics to be examined as part of their therapy

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Determination of concentration differences of common psychotropic drugs / substitution therapeutics in whole blood and serum and in the presence / absence of the esterase inhibitor sodium fluoride	—

Secondary

Measure	Time frame
No secondary end point	—

Countries

Germany

Contacts

Public ContactPeter Heese

LVR-Klinik Bonn

Peter.Heese@lvr.de02285512800

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026